The discovery of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) at the end of 2019 has placed an unprecedented strain on our global healthcare systems, economies, and individual livelihood. In the absence of a vaccine, safe and reliable testing is critical for accurate tracking of cases, timely contact tracing in the community, and isolation of infected individuals. The speed and volume of such innovations require the dedication of immense regulatory resources that no single country can or should manage alone. Thus, it is apt timing for governments to examine whether their emergency regulatory mechanisms are truly agile, and consider what can be learnt from the regulatory experiences of other countries.
Download the paper here (English Version)
